Clinical Trial Update: Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and safety of Boostrix Polio as a booster dose in 5- to 6-year-old children; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Polio
• Tetanus

Drugs mentioned

• Boostrix Polio vaccine (Diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2017-04-18